Steliou, Kosta2020-04-092020-04-092019-03-13Kosta Steliou. 2019. "Neuroprotective effects of carnitinoid compounds in rodent cellular and in vivo models of mitochondrial complex I dysfunction." Volume 2, pp. 26 - 33.https://hdl.handle.net/2144/40078Rotenone-mediated mitochondrial complex I inhibition was used to model Parkinson’s disease-like syndrome in Lewis rats. Tyrosine hydroxylase immunolabeling demonstrated a decrease in the number of dopaminergic neurons as well as aberrant morphology in surviving neurons. Administration of carnitinoid compounds (synthetic lipoylcarnitine or butyrylcarnitine compounds) reduced dopaminergic neuronal cell loss with characteristic morphology observed in surviving neurons. In a rat primordial hippocampal cell line (H19-7/IGF-IR), rotenone treatment resulted in increased ROS and reduced cellular ATP, while co-treatment with lipoylcarnitine maintained ROS and ATP at control levels. These results illustrate the therapeutic potential of small-molecule carnitinoids in treating neurodegenerative diseases associated with mitochondrial dysfunction.pp. 26 - 33© 2018 Mesford Publisher INC. This is an open access article licensed under the term of the Creative Commons Attribution-Non Commercial 4.0 International License (Attribution-NonCommercial 4.0 International-CC-BY-NC 4.0)http://creativecommons.org/licenses/by-nc/4.0/MitochondriaComplex ICarnitinoidsRodent modelingNeurodegenerationParkinson's diseaseArticle0000-0002-5530-3194 (Steliou, Kosta)502646